✦ LIBER ✦

Management of Lower-Risk Myelodysplastic Syndromes:The Art and Evidence

✍ Scribed by Rami S. Komrokji; Mikkael A. Sekeres; Alan F. List

Book ID: 107540309
Publisher: Current Science Inc.
Year: 2011
Tongue: English
Weight: 248 KB
Volume: 6
Category: Article
ISSN: 1558-8211
DOI: 10.1007/s11899-011-0086-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Myelodysplastic syndromes in children. A

Myelodysplastic syndromes in children. A critical review of the clinical manifestations and management

✍ Novitzky, Nicolas 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB 👁 3 views

The FAB group has defined myelodysplasia in adults but direct application of this categorization to children has been controversial. Consequently, to outline the natural history of the disease better we have retrospectively analysed case reports and series published in English between 1982 and 1996.

Cause of death in patients with lower-ri

Cause of death in patients with lower-risk myelodysplastic syndrome

✍ Farshid Dayyani; Anthony P. Conley; Sara S. Strom; William Stevenson; Jorge E. C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 212 KB

Fludarabine, cytarabine, and granulocyte

Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes

✍ Felicetto Ferrara; Franco Leoni; Antonio Pinto; Salvatore Mirto; Enrica Morra; V 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## BACKGROUND. The prognosis of patients with high risk myelodysplastic syndromes (MDS) (i.e., refractory anemia with excess of blasts [RAEB] and refractory anemia with excess of blasts in transformation [RAEB-t]) usually is poor. The combination of fludarabine, cytarabine, and granulocyte-colony

Azacitidine for the treatment of lower r

Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program

✍ Pellegrino Musto; Luca Maurillo; Alessandra Spagnoli; Antonella Gozzini; Flavia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

## Abstract ## BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high‐risk myelodysplastic syndromes (MDS). However, limited data are available concerning the efficacy and safety of azacitidine in patients who have

Quantification of outpatient management

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

✍ J. A. Pitako; P. S. Haas; J. Van den Bosch; H. Müller-Berndorff; A. Kündgen; U. 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 114 KB

High-dose darbepoetin alpha in the treat

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

✍ L. Mannone; C. Gardin; M. C. Quarre; J. F. Bernard; D. Vassilieff; L. Ades; S. P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB